NZ333813A - Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonist - Google Patents
Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonistInfo
- Publication number
- NZ333813A NZ333813A NZ333813A NZ33381397A NZ333813A NZ 333813 A NZ333813 A NZ 333813A NZ 333813 A NZ333813 A NZ 333813A NZ 33381397 A NZ33381397 A NZ 33381397A NZ 333813 A NZ333813 A NZ 333813A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antagonist
- pharmaceutical composition
- 5ht2c
- composition containing
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A pharmaceutical composition for treating or prevention of CNS disorders like schizophrenia comprising: a) a compound having 5HT2c antagonist being 5-methyl-6-trifluoromethyl-1-[6-(2-methylpyridin-3-yloxy)pyridin-3-ylcarbamoyl]indoline, b) a compound having D2 antagonist activity, selected from ziprasidone, olanzapine, sertindole or quetiapine c) a carrier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9615767.2A GB9615767D0 (en) | 1996-07-26 | 1996-07-26 | Novel treatment |
| PCT/EP1997/004159 WO1998004289A2 (en) | 1996-07-26 | 1997-07-22 | Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ333813A true NZ333813A (en) | 2000-07-28 |
Family
ID=10797573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ333813A NZ333813A (en) | 1996-07-26 | 1997-07-22 | Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonist |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0936924A2 (en) |
| JP (1) | JP2000516924A (en) |
| KR (1) | KR20000029564A (en) |
| CN (1) | CN1230894A (en) |
| AR (1) | AR008083A1 (en) |
| AU (1) | AU725817B2 (en) |
| BR (1) | BR9710568A (en) |
| CA (1) | CA2261813A1 (en) |
| CO (1) | CO5031292A1 (en) |
| CZ (1) | CZ23799A3 (en) |
| GB (1) | GB9615767D0 (en) |
| HU (1) | HUP9903619A3 (en) |
| IL (1) | IL128219A0 (en) |
| NO (1) | NO990322L (en) |
| NZ (1) | NZ333813A (en) |
| PL (1) | PL331426A1 (en) |
| TR (1) | TR199900140T2 (en) |
| WO (1) | WO1998004289A2 (en) |
| ZA (1) | ZA976593B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9612883D0 (en) * | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| US6174882B1 (en) | 1998-11-23 | 2001-01-16 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
| ES2211205T3 (en) * | 1998-11-23 | 2004-07-01 | Sepracor Inc. | PHARMACEUTICAL COMPOSITIONS CONTAINING OLANZAPINE-N-OXIDE. |
| PT1133300E (en) | 1998-11-23 | 2005-04-29 | Sepracor Inc | DESMETILOLANZAPINE COMPOSITIONS AND METHODS |
| WO2000054764A2 (en) * | 1999-03-18 | 2000-09-21 | Children's Hospital Research Foundation | A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications |
| CA2363784A1 (en) * | 1999-05-19 | 2000-11-30 | Astrazeneca Ab | Method of treatment |
| WO2005013969A1 (en) * | 2003-07-15 | 2005-02-17 | Janssen Pharmaceutica N.V. | Antipsychotic agent with socializing properties |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9500998D0 (en) * | 1995-03-19 | 1995-03-19 | Haakan Wilhelm Wikstroem | New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics |
-
1996
- 1996-07-26 GB GBGB9615767.2A patent/GB9615767D0/en active Pending
-
1997
- 1997-07-22 CZ CZ99237A patent/CZ23799A3/en unknown
- 1997-07-22 EP EP97918947A patent/EP0936924A2/en not_active Ceased
- 1997-07-22 KR KR1019997000622A patent/KR20000029564A/en not_active Application Discontinuation
- 1997-07-22 CN CN97197977A patent/CN1230894A/en active Pending
- 1997-07-22 WO PCT/EP1997/004159 patent/WO1998004289A2/en not_active Application Discontinuation
- 1997-07-22 BR BR9710568A patent/BR9710568A/en not_active Application Discontinuation
- 1997-07-22 NZ NZ333813A patent/NZ333813A/en unknown
- 1997-07-22 JP JP10508522A patent/JP2000516924A/en active Pending
- 1997-07-22 HU HU9903619A patent/HUP9903619A3/en unknown
- 1997-07-22 AU AU42972/97A patent/AU725817B2/en not_active Ceased
- 1997-07-22 PL PL97331426A patent/PL331426A1/en unknown
- 1997-07-22 IL IL12821997A patent/IL128219A0/en unknown
- 1997-07-22 TR TR1999/00140T patent/TR199900140T2/en unknown
- 1997-07-22 CA CA002261813A patent/CA2261813A1/en not_active Abandoned
- 1997-07-24 AR ARP970103348A patent/AR008083A1/en not_active Application Discontinuation
- 1997-07-24 ZA ZA976593A patent/ZA976593B/en unknown
- 1997-07-25 CO CO97042582A patent/CO5031292A1/en unknown
-
1999
- 1999-01-25 NO NO990322A patent/NO990322L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR008083A1 (en) | 1999-12-09 |
| WO1998004289A2 (en) | 1998-02-05 |
| NO990322L (en) | 1999-03-24 |
| GB9615767D0 (en) | 1996-09-04 |
| JP2000516924A (en) | 2000-12-19 |
| CN1230894A (en) | 1999-10-06 |
| PL331426A1 (en) | 1999-07-19 |
| EP0936924A2 (en) | 1999-08-25 |
| IL128219A0 (en) | 1999-11-30 |
| AU4297297A (en) | 1998-02-20 |
| KR20000029564A (en) | 2000-05-25 |
| CA2261813A1 (en) | 1998-02-05 |
| TR199900140T2 (en) | 1999-03-22 |
| NO990322D0 (en) | 1999-01-25 |
| CO5031292A1 (en) | 2001-04-27 |
| BR9710568A (en) | 1999-08-17 |
| CZ23799A3 (en) | 1999-06-16 |
| HUP9903619A3 (en) | 2001-03-28 |
| WO1998004289A3 (en) | 1998-03-19 |
| AU725817B2 (en) | 2000-10-19 |
| HUP9903619A2 (en) | 2000-10-28 |
| ZA976593B (en) | 1999-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9601419A3 (en) | Synergetic pharmaceutical compositions for treating parkinson-disease | |
| HU9602932D0 (en) | Substituted imidazolidine-2,4-dion compounds as pharmaceutical agent | |
| HUP0101627A3 (en) | Pharmaceutical compositions for treating neuropsychiatric disorders | |
| NZ513889A (en) | Kappa agonist compounds, pharmaceutical formulations and methods of prevention and treatment of pruritus therewith | |
| AU9298098A (en) | Amino-substituted compounds, methods, and compositions for inhibiting parp activity | |
| HU9600765D0 (en) | Use of a cgrp antagonist for treating skin redness of neurogenic origin, and compositions containing these compounds | |
| IL127244A0 (en) | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | |
| HUP0103344A3 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them | |
| EP0825867A4 (en) | N,o-carboxymethylchitosan for prevention of surgical adhesions | |
| PL330752A1 (en) | Pharmaceutical agent for treating urinary incontinence | |
| HUP9602943A3 (en) | Composition for inhibiting angiogenesis | |
| AU9298198A (en) | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity | |
| ZA9811629B (en) | The use of MMP inhibitors for the treatment of ocular angiogenesis. | |
| HUT73854A (en) | Antipsychotic pharmaceutical compositions containing azabicyclo-thiadiazolo- or azabicyclo-oxadiazolo-derivatives | |
| NZ333813A (en) | Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonist | |
| HU9801924D0 (en) | Pharmaceutica composition for treating heart- and vascular troubles containing sodium-hydrogen-change-inhibitors | |
| PL312908A1 (en) | Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors | |
| IL132520A0 (en) | A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor | |
| HUP0100611A3 (en) | Triazine compounds for treatment of cns disorders | |
| GB9611614D0 (en) | Process for inhibiting the effect of flourescent whitening agents | |
| IL117970A (en) | Pharmaceutical compositions containing olanzapine for treating nicotine withdrawal | |
| HU9800396D0 (en) | Pharmaceutical composition for treating dementia | |
| EP1009403A4 (en) | Method for treating schizophrenia | |
| GB2305370B (en) | Device for depletion of leukocytes | |
| HUT74745A (en) | Pharmaceutical compositions containing p antagonist for treating pruritis, eye- and eyelid-acs and eye-and eyelid dysaesthesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |